rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

Patrick J. Heron

Director

Company insider

Files Form 4 as: Director and 10% owner, Mirum Pharmaceuticals; Director and 10% owner, Arcutis Biotherapeutics; Director and 10% owner, MBX Biosciences; Director and 10% owner, HilleVax; Director, Imago BioSciences; Director, Vaxcyte; Director and 10% owner, Iterum Therapeutics; Director and 10% owner, Passage Bio.

Every Form 4 they filed

In numbers

Trades disclosed
194
Buys
37
Sells
0
Bought
$104.9M
Sold
$0
Companies
16
Companies where not an officer
16
First trade
23 Oct 2006
Last trade
15 Jun 2026
Last filed
17 Jun 2026

Companies traded

Everywhere else they filed: board seats, 10% stakes, other companies
MIRM Mirum PharmaceuticalsDirector, 10% owner · Biotechnology · last 15 Jun 202617 buys · 0 sells
ARQT Arcutis BiotherapeuticsDirector, 10% owner · Biotechnology · last 5 Jun 202611 buys · 0 sells
MBX MBX BiosciencesDirector, 10% owner · Biotechnology · last 4 Jun 20261 buy · 0 sells
HilleVaxDirector, 10% owner · last 23 Jun 20250 buys · 0 sells
Imago BioSciencesDirector · last 15 Jul 20210 buys · 0 sells
PCVX VaxcyteDirector · Biotechnology · last 2 Jun 20211 buy · 0 sells
Iterum TherapeuticsDirector, 10% owner · last 1 Jul 20201 buy · 0 sells
PASG Passage BioDirector, 10% owner · Biotechnology · last 3 Mar 20201 buy · 0 sells
PHAT Phathom Pharmaceuticals10% owner · Biotechnology · last 29 Oct 20191 buy · 0 sells
Entasis Therapeutics Holdings10% owner · last 28 Sep 20181 buy · 0 sells
ANAB AnaptysBio10% owner · Biotechnology · last 31 Jan 20171 buy · 0 sells
Tobira TherapeuticsDirector · last 1 Nov 20160 buys · 0 sells

Activity over time

1 Nov 2024 – 1 Oct 2026
08Nov 24May 25Nov 25Apr 26Oct 26

Buys above the line, sells below, each month.

Every trade

TradedCompanyWhatAmount
15 Jun 2026filed 17 Jun 2026MIRM Mirum Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code A—3,772 at $0.00filing
15 Jun 2026filed 17 Jun 2026MIRM Mirum Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code A—1,980 at $0.00filing
15 Jun 2026filed 17 Jun 2026MIRM Mirum Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code A—3,772 at $0.00filing
15 Jun 2026filed 17 Jun 2026MIRM Mirum Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code A—1,980 at $0.00filing
5 Jun 2026filed 9 Jun 2026ARQT Arcutis BiotherapeuticsBiotechnologySEC FORM 4 Code A—5,778 at $0.00filing
5 Jun 2026filed 9 Jun 2026ARQT Arcutis Biotherapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—16,667 at $0.00filing
5 Jun 2026filed 9 Jun 2026ARQT Arcutis Biotherapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—16,667 at $0.00filing
5 Jun 2026filed 9 Jun 2026ARQT Arcutis BiotherapeuticsBiotechnologySEC FORM 4 Code A—5,778 at $0.00filing
4 Jun 2026filed 5 Jun 2026MBX MBX Biosciencesoption or derivative · BiotechnologySEC FORM 4 Code A—12,500 at $0.00filing
4 Jun 2026filed 5 Jun 2026MBX MBX Biosciencesoption or derivative · BiotechnologySEC FORM 4 Code A—12,500 at $0.00filing
23 Jan 2026filed 27 Jan 2026MIRM Mirum PharmaceuticalsBiotechnologySEC FORM 4 Code J—159,277filing
23 Jan 2026filed 27 Jan 2026MIRM Mirum PharmaceuticalsBiotechnologySEC FORM 4 Bought$9.0M131,425 at $68.48filing
23 Jan 2026filed 27 Jan 2026MIRM Mirum PharmaceuticalsBiotechnologySEC FORM 4 Code J—159,277filing
23 Jan 2026filed 27 Jan 2026MIRM Mirum PharmaceuticalsBiotechnologySEC FORM 4 Bought$9.0M131,425 at $68.48filing
23 Jun 2025filed 25 Jun 2025HilleVaxSEC FORM 4 Code A—17,199 at $0.00filing
13 Jun 2025filed 17 Jun 2025ARQT Arcutis BiotherapeuticsBiotechnologySEC FORM 4 Bought$35K2,646 at $13.08filing
12 Jun 2025filed 16 Jun 2025ARQT Arcutis Biotherapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—20,568 at $0.00filing
12 Jun 2025filed 16 Jun 2025ARQT Arcutis BiotherapeuticsBiotechnologySEC FORM 4 Code A—7,609 at $0.00filing
5 Jun 2025filed 6 Jun 2025MBX MBX Biosciencesoption or derivative · BiotechnologySEC FORM 4 Code A—16,000 at $0.00filing
5 Jun 2025filed 6 Jun 2025ARQT Arcutis BiotherapeuticsBiotechnologySEC FORM 4 Bought$5,069378 at $13.41filing

News

Mirum Pharmaceuticals to report Livmarli trial results Monday (MIRM:NASDAQ)MIRM · seekingalpha.com · 12 Oct 2026

0 headlines in the last 90 days name Patrick J. Heron; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.

Sectors

Health Care34
Not placed3

Buys in green, sells in red, by the company’s sector.

Related people

Peter RadovichDirector · Director at MBX Biosciences, filing Form 4 there in the last year
Jolanda HoweSVP, Global Controller · SVP, Global Controller at Mirum Pharmaceuticals, filing Form 4 there in the last year
Howard G. WelgusDirector · Director at Arcutis Biotherapeutics, filing Form 4 there in the last year
Robert Paul MyersChief Medical Officer · Chief Medical Officer at Mirum Pharmaceuticals, filing Form 4 there in the last year
Christopher PeetzChief Executive Officer · Chief Executive Officer at Mirum Pharmaceuticals, filing Form 4 there in the last year
Elvia CowanSVP, Finance & CAO · Also traded PCVX in the last 90 days
Jim WassilEVP, Chief Scientific Ofc, COO · Also traded PCVX in the last 90 days
Hollings RentonDirector · Also traded ANAB in the last 90 days